Publication Type : Scientific reports
Publisher : National Library of Medicine
Source : Indian J Palliat Care. 2013 Jan;19(1):48-53. doi: 10.4103/0973-1075.110237. PMID: 23766595; PMCID: PMC3680839.
Campus : Kochi
School : School of Medicine
Year : 2013
Abstract : Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor, represents a new treatment option for patients with advanced non-small-cell lung cancer (NSCLC). We analyzed the data of patients who received Gefitinib for NSCLC in a tertiary care center in South India.
Cite this Research Publication : Mehta AA, Jose WM, Pavithran K, Triavadi GS. The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India. Indian J Palliat Care. 2013 Jan;19(1):48-53. doi: 10.4103/0973-1075.110237. PMID: 23766595; PMCID: PMC3680839.